Evidence map›Paper›PMID 37278102›Full record

ArticleCancer cytopathology2023

Diagnosis of thoracic SMARCA4-deficient undifferentiated tumor in cytology.

Brie Kezlarian, Joseph Montecalvo, Francis M Bodd, Jason C Chang, Elyn Riedel, Charlie White, Natasha Rekhtman, Jennifer L Sauter

Open access · hybridAbstract read
In one paragraph

Article in Cancer cytopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. The role of SMARCA4 in lung cancer.Scientific reports · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Brie KezlarianDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-0539-8321
Joseph MontecalvoDepartment of Pathology, Henry Ford Hospital, Detroit, MI, USA.
Francis M BoddDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jason C ChangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elyn RiedelDepartment of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Charlie WhiteDepartment of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1671-3155
Natasha RekhtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jennifer L SauterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6987-2294
Memorial Sloan Kettering Cancer Center · USHenry Ford Hospital · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionAlthough alterations in SMARCA4-deficient occur in non-small cell lung carcinoma (SD-NSCLC), thoracic SMARCA4-deficient undifferentiated tumor (TSDUT) is recognized as a distinct entity in the 2021 World Health Organization Classification of Thoracic Tumors because of unique morphologic, immunophenotypic and molecular features, and worse survival compared with SD-NSCLC. Cytologic diagnosis of TSDUT is clinically important because of its aggressive behavior and because it is often diagnosed by fine-needle aspiration because TSDUTs are usually unresectable at presentation. Here, we identify cytologic features that can be used for recognition of TSDUT and distinction from SD-NSCLC. MATERIALS AND

methodsCytomorphologic features were investigated in cytology specimens from patients with TSDUT (n = 11) and compared with a control group of patients with SD-NSCLC (n = 20).

resultsThe presence of classic rhabdoid morphology, at least focally, was entirely specific for TSDUT (n = 6, 55%) compared with SD-NSCLC (n = 0) in this study. TSDUT more frequently showed tumor necrosis (n = 11, 100% vs. n = 8, 40%; p = .001), dominant single-cell pattern on aspirate smears or touch preparation slides (n = 8 [of 9], 80% vs. n = 3, 15%; p = .010), nuclear molding (n = 5, 45% vs. n = 1, 5%; p = .013), and indistinct cell borders (n = 11, 100% vs. n = 5, 25%; P < .001) compared with SD-NSCLC, respectively.

conclusionsCytomorphologic features occurring more frequently in TSDUT include tumor necrosis, dominant single-cell pattern, nuclear molding indistinct cell borders, and focal rhabdoid cells. Presence of these features in a cytology specimen of an undifferentiated tumor, particularly in a patient with a thoracic mass, should raise suspicion for TSDUT and prompt appropriate ancillary workup.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaThoracic NeoplasmsBiomarkers, TumorCytological TechniquesDNA HelicasesHumansNecrosisNuclear ProteinsTranscription FactorsBiomarkers, TumorDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factorscytopathologynon-small cell lung carcinoma (NSCLC)SMARCA4-deficient thoracic sarcomatoid tumor (SD-TST)thoracic SMARCA4-deficient undifferentiated tumor (TSDUT)thoracic tumors

Identifiers

PMID37278102
PMCPMC11037264
OpenAlexW4379509063

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.